Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C30H48O3 |
Molecular Weight | 456.7003 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12[C@@H](CC[C@@]1(CC[C@]3(C)[C@]2([H])CC[C@]4([H])[C@@]5(C)CC[C@H](O)C(C)(C)[C@]5([H])CC[C@@]34C)C(O)=O)C(C)=C
InChI
InChIKey=QGJZLNKBHJESQX-FZFNOLFKSA-N
InChI=1S/C30H48O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-24,31H,1,8-17H2,2-7H3,(H,32,33)/t19-,20+,21-,22+,23-,24+,27-,28+,29+,30-/m0/s1
Molecular Formula | C30H48O3 |
Molecular Weight | 456.7003 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 10 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Betulinic acid (BA) is a plant-derived pentacyclic triterpenoid that exerts potent anti-cancer effects in vitro and in vivo. It`s anticancer property is linked to its ability to induce apoptotic cell death in cancer cells by triggering the mitochondrial pathway of apoptosis. In contrast to the cytotoxicity of betulinic acid against a variety of cancer types, normal cells and tissue are relatively resistant to betulinic acid, pointing to a therapeutic window. Compounds that exert a direct action on mitochondria present promising experimental cancer therapeutics, since they may trigger cell death under circumstances in which standard chemotherapeutics fail. Thus, mitochondrion-targeted agents such as betulinic acid hold great promise as a novel therapeutic strategy in the treatment of human cancers. Betulinic acid has antiretroviral, antimalarial, and anti-inflammatory properties. Betulinic acid exerts its inhibitory effect by preventing topoisomerase I-DNA interaction as a result of which the 'cleavable complex' is not formed. In consequence, it also acts as an antagonist to camptothecin-mediated cleavage. The antitumor pharmacological effects of BA consist of triggering apoptosis via the mitochondrial pathway, regulating the cell cycle and the angiogenic pathway via factors, including specificity protein transcription factors, cyclin D1 and epidermal growth factor receptor, inhibiting the signal transducer and activator of transcription 3 and nuclear factor‑κB signaling pathways, preventing the invasion and metastasis of tumor cells, and affecting the expression of topoisomerase I, p53 and lamin B1. Betulinic Acid has also been used in trials studying the treatment of Dysplastic Nevus Syndrome. Betulinic acid acts as anti-melanoma agent through inhibiting aminopeptidase N activity with IC50 of 7.3 uM. Betulinic acid is an inhibitor of HIV-1 with EC50 of 1.4 uM.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23401880 | https://www.ncbi.nlm.nih.gov/pubmed/24151877
Curator's Comment: Betulinic acid (BA) is able to cross the blood-brain barrier
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26535952
Curator's Comment: Johann Tobias Lowitz (1788) was the first to identify and isolate Betulinic acid (BetA) from the outer bark of white-barked birch trees. He found BetA was a major constituent.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1075164 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12118187 |
5.0 µM [IC50] | ||
Target ID: map04210 |
|||
Target ID: CHEMBL378 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8176401 |
1.4 µM [EC50] | ||
Target ID: CHEMBL1907 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9810272 |
7.3 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
25.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17596104 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BETULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
25.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17596104 |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BETULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
382.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17596104 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BETULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1113.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17596104 |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BETULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
62.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17596104 |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
BETULINIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.01% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12955738 |
BETULINIC ACID plasma | Mus musculus population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
250 mg single, oral Highest studied dose Dose: 250 mg Route: oral Route: single Dose: 250 mg Sources: Page: p.3577 |
unhealthy, ADULT Health Status: unhealthy Condition: HIV infection Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: Page: p.3577 |
|
200 mg 1 times / day multiple, oral Studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: Page: p.594 |
healthy, ADULT n = 6 Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Population Size: 6 Sources: Page: p.594 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 >50 uM] | ||||
no [IC50 >50 uM] | ||||
no | ||||
weak | ||||
yes [IC50 0.1386 uM] | ||||
yes [IC50 1.286 uM] | ||||
yes [IC50 16.98 uM] | ||||
yes [IC50 20.8 uM] | ||||
yes [IC50 21.37 uM] | ||||
yes [IC50 24.06 uM] | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Quantitative analysis of betulinic acid in mouse, rat and dog plasma using electrospray liquid chromatography/mass spectrometry. | 2003 |
|
New ursolic and betulinic derivatives as potential cytotoxic agents. | 2003 Apr |
|
News from the bench. | 2003 Dec |
|
Immunomodulatory activity of betulinic acid by producing pro-inflammatory cytokines and activation of macrophages. | 2003 Dec |
|
New lupane derived compounds with pro-apoptotic activity in cancer cells: synthesis and structure-activity relationships. | 2003 Dec 4 |
|
Dihydrobetulinic acid induces apoptosis in Leishmania donovani by targeting DNA topoisomerase I and II: implications in antileishmanial therapy. | 2003 Jan-Feb |
|
Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation. | 2003 Jul |
|
Antiviral activity of betulin, betulinic and betulonic acids against some enveloped and non-enveloped viruses. | 2003 Jul |
|
[Synthesis and antiviral activity of hydrazides and substituted benzalhydrazides of betulinic acid and its derivatives]. | 2003 May-Jun |
|
Cytotoxic triterpenoids from the fruits of Zizyphus jujuba. | 2003 Nov |
|
A new acylated oleanane triterpenoid from Couepia polyandra that inhibits the lyase activity of DNA polymerase beta. | 2003 Nov |
|
Antitumor-promoting constituents from Chaenomeles sinensis KOEHNE and their activities in JB6 mouse epidermal cells. | 2003 Nov |
|
[Synthesis and antiviral activity of ureides and carbamates of betulinic acid and its derivatives]. | 2003 Nov-Dec |
|
Antiplasmodial triterpenes from twigs of Gardenia saxatilis. | 2003 Oct |
|
Lupane triterpenes and derivatives with antiviral activity. | 2003 Oct 20 |
|
Betulinic acid: a new cytotoxic compound against malignant head and neck cancer cells. | 2003 Sep |
|
Betulinic acid suppresses carcinogen-induced NF-kappa B activation through inhibition of I kappa B alpha kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9. | 2003 Sep 15 |
|
Apoptosis of human carcinoma cells in the presence of potential anti-cancer drugs: III. Treatment of Colo-205 and SKBR3 cells with: cis -platin, Tamoxifen, Melphalan, Betulinic acid, L-PDMP, L-PPMP, and GD3 ganglioside. | 2004 |
|
Cytotoxic lupane-type triterpenoids from Acacia mellifera. | 2004 Apr |
|
Betulinic acid: a promising anticancer candidate. | 2004 Apr |
|
Marmenol: a 7-geranyloxycoumarin from the leaves of Aegle marmelos Corr. | 2004 Apr |
|
Betulinic acid augments the inhibitory effects of vincristine on growth and lung metastasis of B16F10 melanoma cells in mice. | 2004 Apr 19 |
|
Rapid analysis of triterpenic acids by liquid chromatography using porous graphitic carbon and evaporative light scattering detection. | 2004 Aug |
|
[Inhibitory effects of some traditional medicines on proliferation of HIV-1 and its protease]. | 2004 Aug |
|
Betulinic acid-induced apoptosis in leukemia cells. | 2004 Aug |
|
Synthesis and cytotoxic activity of 3-O-acyl/3-hydrazine /2-bromo/20,29-dibromo betulinic acid derivatives. | 2004 Aug 2 |
|
Phenolic compounds obtained from stems of Couepia ulei with the potential to induce quinone reductase. | 2004 Feb |
|
Antiplasmodial constituents of Cajanus cajan. | 2004 Feb |
|
Phytotoxic and antimicrobial constituents of Bacopa monnieri and Holmskioldia sanguinea. | 2004 Feb |
|
Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. | 2004 Feb 1 |
|
Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process. | 2004 Jan |
|
New prenylated isoflavanones and other constituents of Lespedeza bicolor. | 2004 Jan |
|
Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. | 2004 Jan |
|
Erythrocyte membrane modifying agents and the inhibition of Plasmodium falciparum growth: structure-activity relationships for betulinic acid analogues. | 2004 Jan 2 |
|
Synthesis of A-seco derivatives of betulinic acid with cytotoxic activity. | 2004 Jul |
|
Differential expression of three oxidosqualene cyclase mRNAs in Glycyrrhiza glabra. | 2004 Jul |
|
Betulinic acid enhances 1alpha,25-dihydroxyvitamin D3-induced differentiation in human HL-60 promyelocytic leukemia cells. | 2004 Jul |
|
Cell death induction by betulinic acid, ceramide and TRAIL in primary glioblastoma multiforme cells. | 2004 Jul |
|
Antitubercular constituents of Valeriana laxiflora. | 2004 Jun |
|
New 3-O-acyl betulinic acids from Strychnos vanprukii Craib. | 2004 Jun |
|
Isolation and structure of gustastatin from the Brazilian nut tree Gustavia hexapetala. | 2004 Jun |
|
Quantitative analysis of anti-inflammatory and radical scavenging triterpenoid esters in evening primrose oil. | 2004 Jun 2 |
|
Synthesis of 3-O-acyl/3-benzylidene/3-hydrazone/3-hydrazine/17-carboxyacryloyl ester derivatives of betulinic acid as anti-angiogenic agents. | 2004 Jun 21 |
|
The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid. | 2004 Jun 29 |
|
Lipoxygenase inhibition by anadanthoflavone, a new flavonoid from the aerial parts of Anadenanthera colubrina. | 2004 Mar |
|
Steroids and triterpenes from Eleocharis acutangula and E. sellowiana (Cyperaceae). | 2004 Mar-Apr |
|
Betulinic acid and its derivatives as anti-angiogenic agents. | 2004 May 3 |
|
Protection of Ewing's sarcoma family tumor (ESFT) cell line SK-N-MC from betulinic acid induced apoptosis by alpha-DL-tocopherol. | 2004 Nov 2 |
|
Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells. | 2004 Oct 7 |
|
Apoptotic activity of betulinic acid derivatives on murine melanoma B16 cell line. | 2004 Sep 13 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00346502
Treatment will consist of four weeks of daily application of 20% BA ointment to the dysplastic nevi, after which it will be removed surgically and examined. A similar dysplastic nevi will be removed as a control. Four groups of patients will be enrolled. The first group will apply the ointment once a day, the second twice a day, the third three times a day, and the fourth four times a day.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12118187
Betulinic acid inhibits rat topoisomerase I in a dose dependent
manner, with complete inhibition of
enzyme activity achieved at 10 uM concentration. Betulinic acid at a concentration of 2.5 uM does not inhibit the enzyme activity whereas at 5 uM concentration 50% inhibition is achieved.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:24:16 GMT 2023
by
admin
on
Fri Dec 15 16:24:16 GMT 2023
|
Record UNII |
4G6A18707N
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2139
Created by
admin on Fri Dec 15 16:24:16 GMT 2023 , Edited by admin on Fri Dec 15 16:24:16 GMT 2023
|
||
|
FDA ORPHAN DRUG |
244107
Created by
admin on Fri Dec 15 16:24:16 GMT 2023 , Edited by admin on Fri Dec 15 16:24:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
113090
Created by
admin on Fri Dec 15 16:24:16 GMT 2023 , Edited by admin on Fri Dec 15 16:24:16 GMT 2023
|
PRIMARY | |||
|
C38126
Created by
admin on Fri Dec 15 16:24:16 GMT 2023 , Edited by admin on Fri Dec 15 16:24:16 GMT 2023
|
PRIMARY | |||
|
C002070
Created by
admin on Fri Dec 15 16:24:16 GMT 2023 , Edited by admin on Fri Dec 15 16:24:16 GMT 2023
|
PRIMARY | |||
|
DB12480
Created by
admin on Fri Dec 15 16:24:16 GMT 2023 , Edited by admin on Fri Dec 15 16:24:16 GMT 2023
|
PRIMARY | |||
|
m2463
Created by
admin on Fri Dec 15 16:24:16 GMT 2023 , Edited by admin on Fri Dec 15 16:24:16 GMT 2023
|
PRIMARY | Merck Index | ||
|
3087
Created by
admin on Fri Dec 15 16:24:16 GMT 2023 , Edited by admin on Fri Dec 15 16:24:16 GMT 2023
|
PRIMARY | |||
|
64971
Created by
admin on Fri Dec 15 16:24:16 GMT 2023 , Edited by admin on Fri Dec 15 16:24:16 GMT 2023
|
PRIMARY | |||
|
207-448-8
Created by
admin on Fri Dec 15 16:24:16 GMT 2023 , Edited by admin on Fri Dec 15 16:24:16 GMT 2023
|
PRIMARY | |||
|
4G6A18707N
Created by
admin on Fri Dec 15 16:24:16 GMT 2023 , Edited by admin on Fri Dec 15 16:24:16 GMT 2023
|
PRIMARY | |||
|
472-15-1
Created by
admin on Fri Dec 15 16:24:16 GMT 2023 , Edited by admin on Fri Dec 15 16:24:16 GMT 2023
|
PRIMARY | |||
|
677578
Created by
admin on Fri Dec 15 16:24:16 GMT 2023 , Edited by admin on Fri Dec 15 16:24:16 GMT 2023
|
PRIMARY | |||
|
DTXSID80861974
Created by
admin on Fri Dec 15 16:24:16 GMT 2023 , Edited by admin on Fri Dec 15 16:24:16 GMT 2023
|
PRIMARY | |||
|
BETULINIC ACID
Created by
admin on Fri Dec 15 16:24:17 GMT 2023 , Edited by admin on Fri Dec 15 16:24:17 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |